INDOCO vs SUPRIYA: Stock Comparison
SUPRIYA LIFESCIENCE is the larger company by market capitalisation. SUPRIYA LIFESCIENCE shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
INDOCO leads 2; SUPRIYA leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | INDOCO | SUPRIYA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | INDOCO | SUPRIYA |
|---|---|---|
| Live Price | ₹225.6 | ₹836.25 |
| Day Change | -2.55% | -0.75% |
| Volume | 1.07 L | 1.13 L |
| 52-Week High | ₹291 | ₹1,085 |
| 52-Week Low | ₹162.19 | ₹545.5 |
| Distance from 52W High | -22.47% | -22.93% |
Valuation
| Metric | INDOCO | SUPRIYA |
|---|---|---|
| Market Cap | ₹2,077 Cr | ₹6,720 Cr |
| P/E Ratio | 368.85x | 33.87x |
| P/B Ratio | 2.21x | 5.61x |
| EPS | ₹7.04 | ₹2.99 |
| Book Value | ₹100.98 | ₹148.82 |
| Dividend Yield | 0.09% | 0.12% |
Growth
| Metric | INDOCO | SUPRIYA |
|---|---|---|
| Revenue Growth (TTM YoY) | 21.9% | 50.2% |
| EPS Growth (TTM YoY) | 0% | 46.7% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | INDOCO | SUPRIYA |
|---|---|---|
| ROE | -0.51% | 17.46% |
| ROCE | 4.26% | 19.21% |
| Net Margin | -5.31% | 25.26% |
| Operating Margin | 4.57% | 33.42% |
| Debt to Equity | 0.64x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | INDOCO | SUPRIYA |
|---|---|---|
| Promoter Holding | 58.86% | 68.3% |
| FII Holding | 1.27%▲ 0.33 pp | 6.44%▲ 0.25 pp |
| DII Holding | 17.68%▼ 0.47 pp | 5.47%▲ 0.17 pp |
| Public Holding | 22.04%▲ 0.14 pp | 19.79%▼ 0.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOCO REMEDIES and SUPRIYA LIFESCIENCE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.